2-amino—5-substituted pyrimidine inhibitors

1. A compound of structure A:

wherein:

G 1 is selected from a group consisting of an optionally substituted aryl or an optionally substituted heteroaryl;

the moiety L 1 -L 2 is selected from a group consisting of:

A 1 is selected from a group consisting of a bond, NR a , C(O), S(O), S(O) 2 , P(O) 2 , O, S, and C(R a ) 2 , wherein if A 1 is a bond, then the phenyl ring is directly connected to the group A 2 ;

A 2 is selected from a group consisting of NR, C(O), S(O), S(O) 2 , P(O) 2 , O, and S; and the connectivity between the phenyl ring, A 1 , A 2 and the pyrimidine ring are chemically correct;

R a is selected from a group consisting of H, lower alkyl, branched alkyl, hydroxyalkyl, aminoalkyl, thioalkyl, alkylhydroxyl, alklythiol, and alkylamino;

R 3 is selected independently for each occurrence from a group consisting of hydrogen, alkyl, branched alkyl, alkoxy, halogen, CF 3 , cyano, substituted alkyl, hydroxyl, alkylhydroxyl, thiol, alkylthiol, thioalkyl, amino, and aminoalkyl;

n is an integer having value between 0 and 4 inclusive;

the moiety

is selected from a group consisting of:

L 5 is selected from a group consisting of lower alkyl, branched alkyl, CF 3 , cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, bicyclic aryl, bicyclic heteroaryl, bicyclic with one of the rings being aryl or heteroaryl and the other ring being nonaryl, and bicyclic with both rings being nonaryl;

wherein an optionally substituted aryl or heteroaryl, independently for each occurrence, can be substituted on 1, 2, 3, or 4 carbons by alkyl, branched alkyl, alkoxy, halogen, CF 3 , cyano, substituted alkyl, hydroxyl, alkylhydroxyl, thiol, alkylthiol, thioalkyl, amino, and aminoalkyl;

or a pharmaceutically acceptable salt or stereoisomer thereof.

2. The compound of claim 1 having the structure

wherein X is selected from a group consisting of CH and N.

3. The compound of claim 1 having the structure

wherein each of A 1 and A 2 is independently selected from a group consisting of C═O and NH, with the further proviso that when A 1 is NH, A 2 is C═O, and when A 2 is NH, A 1 is C═O.

4. The compound of claim 3 having the structure

5. The compound of claim 4 , wherein L 5 is selected from a group consisting of an optionally substituted aryl or an optionally substituted heteroaryl.

6. The compound of claim 3 having the structure

wherein L 5 is selected from a group consisting of an optionally substituted aryl or an optionally substituted heteroaryl.

7. The compound of claim 6 , wherein L 5 is an optionally substituted aryl.

8. A compound having the structure:

wherein L 5 is a phenyl optionally substituted on 1, 2, 3, 4, or 5 carbons with halogen, alkyl, or CF 3 ;

X is N or CH; and

the moiety L 1 -L 2 is selected from a group consisting of —SO 2 -alkyl-heterocycle, —SO 2 NH-alkyl-heterocycle; SO 2 -heterocycle, —O-alkyl-heterocycle; —C(O)N-alkyl-heterocycle, —C(O)-alkylheterocycle, -alkyl-heterocycle; —O-alkyl; —C(O)O-alkyl; —OH; —OC(O)-phenyl; wherein the heterocycle or the phenyl can be optionally substituted with alkyl, alkoxy, hydroxyalkyl, or halogen;

or a pharmaceutically acceptable salt or stereoisomer thereof.

9. The compound of claim 8 , wherein the optionally substituted heterocycle is selected from a group consisting of azetidine, pyrrolidine, morpholine, piperidine, piperazine, azepane, diazepane, and azocane.

10. A compound having the structure

wherein L 5 is phenyl, optionally substituted with methyl, halogen, or CF 3 ;

R 3 is selected from a group consisting of methyl and chloro, and

X is selected from a group consisting of CH and N; or a pharmaceutically acceptable salt, or stereoisomer thereof.

11. The compound of claim 1 , wherein the compound is selected from the group consisting of compounds X, XLV, XL, XXXVIII, and XXXIX, or a pharmaceutically acceptable salt thereof:

12. The compound of claim 1 , wherein the compound is selected from the group consisting of compounds XXVIII and XLIV, or a pharmaceutically acceptable salt thereof:

13. The compound of claim 1 , wherein the compound is selected from the group consisting of compounds XLIII and XXXIV, or a pharmaceutically acceptable salt thereof:

14. The compound of claim 1 , wherein the compound is selected from the group consisting of compounds XVI, XVII, XX, and XXII, or a pharmaceutically acceptable salt thereof:

15. The compound of claim 1 , wherein the compound is compound XXIII, or a pharmaceutically acceptable salt thereof:

16. The compound of claim 1 , wherein the compound is selected from the group consisting of compounds XVIII and XIX, or a pharmaceutically acceptable salt thereof:

17. The compound of claim 1 , wherein the compound is compound XXI, or a pharmaceutically acceptable salt thereof:

18. The compound of claim 1 , wherein the compound is selected from the group consisting of compounds XXX and XXXI, or a pharmaceutically acceptable salt thereof:

19. The compound of claim 1 , wherein the compound is selected from the group consisting of compounds I, II, III, and IV, or a pharmaceutically acceptable salt thereof:

20. The compound of claim 1 , wherein the compound is selected from the group consisting of compounds VII, XI, XII, XIII, XIV, and XV, or a pharmaceutically acceptable salt thereof:

21. The compound of claim 1 , wherein the compound is compound LII, or a pharmaceutically acceptable salt thereof:

22. The compound of claim 1 , wherein the compound is compound XXIX, or a pharmaceutically acceptable salt thereof:

23. The compound of claim 1 , wherein the compound is selected from the group consisting of compounds VIII and IX, or a pharmaceutically acceptable salt thereof:

24. The compound of claim 1 , wherein the compound is compound XLVII, or a pharmaceutically acceptable salt thereof:

25. The compound of claim 1 , wherein the compound is compound V, or a pharmaceutically acceptable salt thereof:

26. The compound of claim 1 , wherein the compound is compound XLVI, or a pharmaceutically acceptable salt thereof:

27. The compound of claim 1 , wherein the compound is selected from the group consisting of compounds XLI and XLII, or a pharmaceutically acceptable salt thereof:

28. The compound of claim 1 , wherein the compound is compound XXXVII, or a pharmaceutically acceptable salt thereof:

29. The compound of claim 1 , wherein the compound is selected from the group consisting of compounds XXXII and XXIII, or a pharmaceutically acceptable salt thereof:

30. The compound of claim 1 , wherein the compound is compound XL, or a pharmaceutically acceptable salt thereof:

31. The compound of claim 1 , wherein the compound is selected from the group consisting of compounds LVI, LVII, and LX-LXIII, or a pharmaceutically acceptable salt thereof:

32. A pharmaceutical composition comprising at least one compound represented by structure A according to claim 1 and a pharmaceutically acceptable carrier.

33. The pharmaceutical composition of claim 32 , wherein said composition is suitable for oral administration, intravenous administration, topical administration, ocular administration or subcutaneous administration.

34. The pharmaceutical composition of claim 32 , wherein said composition is suitable for ocular administration.